Clene 10% holder sells 65,663 shares

Clene Inc. insider associated entity sells shares in two open-market transactions.

Rhea-AI Filing Summary

Clene Inc. insider associated entity sells shares in two open-market transactions. An entity linked to ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold 4,318 shares of Clene common stock at $6.12 per share on April 20, 2026, followed by 61,345 shares at $6.14 per share on April 21, 2026. After the April 21 sale, the filing reports 297,066 Clene shares indirectly held by this entity.

Insights

Equity analyst

Associated 10% holder sells 65,663 Clene shares but retains a sizable position.

An entity associated with Clene’s ten percent owner Ugwumba Chidozie, SymBiosis II, LLC, executed two open-market sales totaling 65,663 common shares at prices around $6.12–$6.14 per share over April 20–21, 2026. The transactions are reported as indirect ownership changes.

These are straightforward open-market dispositions (code S), with no derivative exercises or tax-related mechanics disclosed. The filing shows 297,066 shares remaining indirectly held after the April 21 sale, indicating the entity continues to hold a substantial stake. Without information on total shares outstanding or any trading plan, the signal from these sales remains limited.

Insider Trade Summary

Net Seller: 65,663 shares

Net Sell 2 txns

Insider Ugwumba Chidozie

Role 10% Owner

Sold 65,663 shs ($403K)

Type	Security	Shares	Price	Value
Sale	Common Stock	61,345	$6.14	$377K
Sale	Common Stock	4,318	$6.12	$26K

Holdings After Transaction: Common Stock — 297,066 shares (Indirect, By SymBiosis II, LLC)

Key Figures

Shares sold April 20, 2026: 4,318 shares at $6.12 Shares sold April 21, 2026: 61,345 shares at $6.14 Total shares sold: 65,663 shares +2 more

5 metrics

Shares sold April 20, 2026 4,318 shares at $6.12 Open-market sale of Clene common stock

Shares sold April 21, 2026 61,345 shares at $6.14 Open-market sale of Clene common stock

Total shares sold 65,663 shares Net shares sold across both transactions

Shares held after April 21 sale 297,066 shares Indirect holdings by SymBiosis II, LLC

Insider status Ten percent owner Reporting person classification on Form 4

Key Terms

open-market sale, ten percent owner, indirect ownership, Common Stock

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ten percent owner regulatory

"reporting person is marked as "ten_percent_owner": 1"

indirect ownership financial

"ownership_type is "indirect" and ownership_code is "I""

Common Stock financial

"security_title": "Common Stock" for each transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Clene (CLNN) report for Ugwumba Chidozie’s associated entity?

An entity linked to ten percent owner Ugwumba Chidozie, SymBiosis II, LLC, reported two open-market sales of Clene common stock on April 20 and 21, 2026, totaling 65,663 shares at prices just above $6.10 per share.

How many Clene (CLNN) shares were sold in the latest Form 4 filing?

The Form 4 shows 65,663 Clene shares sold by SymBiosis II, LLC across two days. The entity sold 4,318 shares at $6.12 on April 20, 2026, and 61,345 shares at $6.14 on April 21, 2026, in open-market transactions.

At what prices were Clene (CLNN) shares sold by SymBiosis II, LLC?

SymBiosis II, LLC sold Clene common stock at two price points: 4,318 shares at $6.12 per share on April 20, 2026, and 61,345 shares at $6.14 per share on April 21, 2026, according to the Form 4 filing.

How many Clene (CLNN) shares does the reporting entity hold after these sales?

After the April 21, 2026 transaction, the Form 4 reports that 297,066 Clene shares are indirectly owned by SymBiosis II, LLC. This remaining balance reflects the holdings following the 61,345-share sale disclosed for that date.

Is the insider ownership in Clene (CLNN) direct or indirect in this Form 4?

The Form 4 characterizes the reported holdings as indirect ownership. Shares are held through SymBiosis II, LLC, as noted by the nature-of-ownership description, rather than being directly registered to Ugwumba Chidozie personally.

Does the Clene (CLNN) Form 4 involve any stock options or derivatives?

The disclosed transactions involve non-derivative common stock only. There are no option exercises, conversions, or other derivative securities listed, and the derivativeSummary section in the filing is empty for this reporting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 05:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE ARKANSAS 72712

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		S		4,318	D	$6.12	358,411	I	By SymBiosis II, LLC
Common Stock	04/21/2026		S		61,345	D	$6.14	297,066	I	By SymBiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Chidozie Ugwumba	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)